MXPA04009929A - Tratamiento de la gastroparesis. - Google Patents

Tratamiento de la gastroparesis.

Info

Publication number
MXPA04009929A
MXPA04009929A MXPA04009929A MXPA04009929A MXPA04009929A MX PA04009929 A MXPA04009929 A MX PA04009929A MX PA04009929 A MXPA04009929 A MX PA04009929A MX PA04009929 A MXPA04009929 A MX PA04009929A MX PA04009929 A MXPA04009929 A MX PA04009929A
Authority
MX
Mexico
Prior art keywords
gastroparesis
treatment
glp
patients
compounds
Prior art date
Application number
MXPA04009929A
Other languages
English (en)
Inventor
Thurman Dwight Mckinney
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MXPA04009929A publication Critical patent/MXPA04009929A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/26Glucagons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

La invencion se refiere al uso de compuestos GLP-1 para tratar gastroparesis. Los pacientes con gastroparesis generalmente experimentan un retraso en el vaciamiento gastrico. Los compuestos GLP-1 pueden ser utilizados para regular el vaciamiento gastrico en esos pacientes.
MXPA04009929A 2002-04-10 2003-03-27 Tratamiento de la gastroparesis. MXPA04009929A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37165002P 2002-04-10 2002-04-10
PCT/US2003/008457 WO2003087139A2 (en) 2002-04-10 2003-03-27 Treatment of gastroparesis

Publications (1)

Publication Number Publication Date
MXPA04009929A true MXPA04009929A (es) 2006-03-10

Family

ID=29250714

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04009929A MXPA04009929A (es) 2002-04-10 2003-03-27 Tratamiento de la gastroparesis.

Country Status (18)

Country Link
US (1) US20050164925A1 (es)
EP (1) EP1496924A4 (es)
JP (1) JP2005530732A (es)
KR (1) KR20040098063A (es)
CN (1) CN1735423A (es)
AU (1) AU2003220403A1 (es)
BR (1) BR0308904A (es)
CA (1) CA2480858A1 (es)
EA (1) EA200401345A1 (es)
EC (1) ECSP045345A (es)
HR (1) HRP20040939A2 (es)
IL (1) IL164266A0 (es)
MX (1) MXPA04009929A (es)
NO (1) NO20044815L (es)
NZ (1) NZ535684A (es)
PL (1) PL373658A1 (es)
WO (1) WO2003087139A2 (es)
ZA (1) ZA200408111B (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8666495B2 (en) 1999-03-05 2014-03-04 Metacure Limited Gastrointestinal methods and apparatus for use in treating disorders and controlling blood sugar
US9101765B2 (en) 1999-03-05 2015-08-11 Metacure Limited Non-immediate effects of therapy
US8792985B2 (en) 2003-07-21 2014-07-29 Metacure Limited Gastrointestinal methods and apparatus for use in treating disorders and controlling blood sugar
EP1667724A2 (en) * 2003-09-19 2006-06-14 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
CA2539253A1 (en) * 2003-09-19 2005-03-31 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
EP1793891B1 (en) 2004-08-18 2011-11-09 Metacure Limited Monitoring, analysis, and regulation of eating habits
WO2006087712A2 (en) 2005-02-17 2006-08-24 Metacure N.V. Charger with data transfer capabilities
US9821158B2 (en) 2005-02-17 2017-11-21 Metacure Limited Non-immediate effects of therapy
KR20070120112A (ko) 2005-03-18 2007-12-21 노보 노르디스크 에이/에스 연장형 glp-1 화합물
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
US8463404B2 (en) 2005-03-24 2013-06-11 Metacure Limited Electrode assemblies, tools, and methods for gastric wall implantation
ATE533403T1 (de) * 2005-03-24 2011-12-15 Metacure Ltd Drahtlose leitungen für magen-darm-trakt- anwendungen
WO2006129321A2 (en) 2005-06-02 2006-12-07 Metacure N.V. Gi lead implantation
US8442841B2 (en) * 2005-10-20 2013-05-14 Matacure N.V. Patient selection method for assisting weight loss
US8295932B2 (en) 2005-12-05 2012-10-23 Metacure Limited Ingestible capsule for appetite regulation
AU2012203915B9 (en) * 2006-04-20 2014-10-09 Amgen Inc. GLP-1 compounds
CA2648936C (en) * 2006-04-20 2013-07-09 Amgen Inc. Glp-1 compounds
EP2150308B1 (en) * 2007-05-09 2018-08-08 MetaCure Limited Analysis and regulation of food intake
US8423130B2 (en) * 2008-05-09 2013-04-16 Metacure Limited Optimization of thresholds for eating detection
KR20110039348A (ko) 2008-08-06 2011-04-15 노보 노르디스크 헬스 케어 악티엔게젤샤프트 연장된 생체내 효능을 가지는 콘쥬게이트된 단백질
KR20110122100A (ko) 2009-01-22 2011-11-09 노보 노르디스크 헬스 케어 악티엔게젤샤프트 안정한 성장 호르몬 화합물
EP2461831B1 (en) 2009-08-06 2018-11-21 Novo Nordisk Health Care AG Growth hormones with prolonged in-vivo efficacy
US8642548B2 (en) * 2009-08-07 2014-02-04 Mannkind Corporation Val (8) GLP-1 composition and method for treating functional dyspepsia and/or irritable bowel syndrome
CN102834109B (zh) 2010-01-22 2016-01-20 诺沃—诺迪斯克保健股份有限公司 稳定的生长激素化合物
JP5980689B2 (ja) 2010-01-22 2016-08-31 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー 安定な成長ホルモン化合物
US8934975B2 (en) 2010-02-01 2015-01-13 Metacure Limited Gastrointestinal electrical therapy
KR20130093470A (ko) 2010-04-30 2013-08-22 가부시키가이샤산와카가쿠켄큐쇼 생리활성 물질 등의 생체 내 안정성 향상을 위한 펩티드 및 생체 내 안정성이 향상된 생리활성 물질
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
AU2013366691A1 (en) 2012-12-21 2015-07-09 Sanofi Exendin-4 derivatives
JP6464145B2 (ja) 2013-04-05 2019-02-06 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー 成長ホルモン化合物製剤

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6268343B1 (en) * 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
CA2283834A1 (en) * 1997-03-31 1998-10-08 James Arthur Hoffmann Glucagon-like peptide-1 analogs
IL142707A0 (en) * 2000-04-27 2002-03-10 Pfizer Prod Inc Methods of treating obesity using a neurotensin receptor ligand

Also Published As

Publication number Publication date
JP2005530732A (ja) 2005-10-13
EP1496924A2 (en) 2005-01-19
IL164266A0 (en) 2005-12-18
EP1496924A4 (en) 2007-05-30
KR20040098063A (ko) 2004-11-18
HRP20040939A2 (en) 2004-12-31
CA2480858A1 (en) 2003-10-23
EA200401345A1 (ru) 2005-08-25
BR0308904A (pt) 2005-05-03
NO20044815L (no) 2005-01-07
CN1735423A (zh) 2006-02-15
US20050164925A1 (en) 2005-07-28
WO2003087139A3 (en) 2004-01-08
WO2003087139A2 (en) 2003-10-23
PL373658A1 (en) 2005-09-05
ECSP045345A (es) 2006-04-19
AU2003220403A1 (en) 2003-10-27
ZA200408111B (en) 2005-10-07
NZ535684A (en) 2006-03-31

Similar Documents

Publication Publication Date Title
MXPA04009929A (es) Tratamiento de la gastroparesis.
EP1534074A4 (en) POLYTHERAPY FOR THE TREATMENT OF OBESITY
MY137757A (en) Therapeutic treatment
WO2006113802A3 (en) Device for administering electrode stimulation of back and abdominal muscles
AU2003300791A1 (en) Combination therapy for the treatment of pain
EP1572095A4 (en) S-L-2 DESOXYNUCLEOSIDE FOR THE TREATMENT OF RESISTANT HBV-STRAINS AND COMBINATION THERAPIES
EP1501489A4 (en) COMBINATION THERAPY FOR THE TREATMENT OF CANCER
HK1085127A1 (en) A use of antipsychotics in the manufacture of medicine delivered by ; inhalation for treatment of headache
WO2005037323A3 (en) Use of gro to treat or prevent inflammation
IL178827A0 (en) Use of reboxetine for the treatment of pain
ZA200501288B (en) Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma.
MXPA04004306A (es) Uso de antagonistas del receptor de endotelina para el tratamiento de enfermedades tumorales.
IL158738A0 (en) Novel use of 2-phenyl-substituted imidazotriazinones
MXPA05001885A (es) El uso de una combinacion de ciclesonida y antihistaminas para el tratamiento de la rinitis alergica.
WO2004004653A3 (en) Methods for treating psychosis associated with interferon-alpha therapy
NZ528164A (en) Use of flumazenil to produce a medicament for the treatment of cocaine dependency
PT1670489E (pt) Utilização de xénon com hipotermia para o tratamento de asfixia neonatal
MXPA05011699A (es) Inhibidores de la bomba de protones para el tratamiento de trastornos del abdomen inferior.
PL1603584T3 (pl) Aplidyna do leczenia szpiczaka mnogiego
PL375584A1 (en) Therapeutic treatment
PL375629A1 (en) 1-phenyl-2-dimethylaminomethyl cyclohexane compounds used for the therapy of depressive symptoms, pain, and incontinence
AU2003255843A1 (en) 1,3-thiazolin-4-ones as therapeutic compounds in the treatment of pain
AU2003270683A8 (en) Compounds for the treatment of premature ejaculation
HUP0300990D0 (en) Synergistic combination for the prophylaxis and treatment of diabetes
IL174134A0 (en) Use of a protein in the preparation of a medicament for treatment of fibrotic diseases

Legal Events

Date Code Title Description
FA Abandonment or withdrawal